

Pathway for patients considered for Omalizumab injections.

Omalizumab is used for the management of persistent, severe Chronic Spontaneous Urticaria (CSU). This is a treatment pathway to ensure patients, considered treatment with Omalizumab, have the appropriate assessments completed.

Name:

NHS no/Hospital number:

Date of Birth:

- 1) Paediatric Consultant considers Omalizumab for treatment of persistent, severe Chronic Spontaneous Urticaria (CSU) following inclusion criteria outlined in Omalizumab guideline 'Investigation, Diagnosis and Management of Chronic Urticaria in Childhood' and 'Omalizumab therapy in children and Young People'

Link: http://whitsweb/KeyDocs/KeyDocs/Sub_Webpage/1178?persist=True

Date and sign: _____

- 2) Patient to complete 4-6 weeks of UAS 7 scores (printed sheets or UAS7 booklets from Novartis kept with allergy CNS team and allergy secretaries)

Link: M:\Acute\Paediatrics\Dr Dawson Clinics\Allergy Patient Info\Urticaria.

Date and sign: _____

- 3) Provides family with Patient Information on Omalizumab

Link: http://whitsweb/KeyDocs/KeyDocs/Sub_Webpage/1179?persist=True

Date and sign: _____

- 4) Assesses any asthma medication, compliance and asthma control. If necessary, performs Peak Flow, FeNo or Spirometry if necessary. Date and sign: _____

- 5) Considers and discusses with young person and family, social arrangements, potential concordance issues and patient concerns. Date and sign: _____

- 6) Discusses patient in MDT and documents in minutes. Date and sign: _____

- 7) Discusses treatment with family and decides plan of action - **proceed** or **withhold treatment** with appropriate follow up (delete as necessary) Date and sign: _____

- 8) Completes BlueTeq pharmacy request. Date and sign: _____

- 9) In patient bed is confirmed. Date and sign: _____

- 10) BRIT registry patient information sheet given to family with explanation.

Date and sign: _____

- 11) In patient prescription chart is completed approximately 2 weeks before admission date to allow pharmacy to order drug. Date and sign: _____

File pathway and UAS7 scores in electronic filing system under 'Investigations/results' when complete.

Additional information to be documented in clinic appointment paperwork and clinic letter.

Only for use by Paediatric Allergy Team